II. Definition
- Euthyroid patient with TSH suppression
- Low but detectable TSH: 0.1 to 0.4 mIU/L
- Suppressed TSH: <0.1 mIU/L (greatest association with adverse effects, esp. >65 years old)
III. Epidemiology
-
Prevalence in U.S. (study included patients over age 12 years old)
- TSH <0.4 mIU/L: 3.2%
- TSH <0.1 mIU/L: 0.7%
- Hollowell (2002) J Clin Endocrinol Metab 87(2): 489-99 [PubMed]
- More common in older adults
- Prevalence in age over 70 years approaches 15% in Iodine deficient regions
- Aghini (1999) J Clin Endocrinol Metab 84(2): 561-6 [PubMed]
IV. Causes
- Over-treatment of Hypothyroidism (excessive Thyroid Replacement)
- Prevalence approaches 20%
- Multinodular Goiter (esp. Iodine-deficient regions)
- Graves Disease
- Functional Thyroid Adenoma
- Transient Thyroiditis
- Silent Thyroiditis (TSH normalizes within months)
- Subacute Thyroiditis
- Postpartum Thyroiditis
- Pituitary abnormalities (Free T4 also suppressed)
- Early Hyperthyroidism in transition
- Partially treated Hyperthyroidism
-
Iodine intake
- Recent radiocontrast administration (e.g. IVP)
- Amiodarone
- Other excessive Iodine intake
- Medications that suppress TSH
- Other conditions
- Sick Euthyroid Syndrome
- Psychiatric illness (esp. affective disorders)
V. Symptoms
- Significant Hyperthyroidism symptoms absent
- Nonspecific symptoms may be present
- Malaise
- Tachycardia
- Nervousness or anxiety
- Muscle Weakness
VI. Differential Diagnosis
- See Hyperthyroidism
- See Thyroid Stimulating Hormone (TSH)
VII. Complications: Primarily for TSH <0.1 mIU/L (undetectable)
- Overt Hyperthyroidism
- TSH 0.1 to 0.4 mIU/L: 1-3% risk per year (in age over 60 years)
- TSH <0.1 mIU/L: 27% 27% risk in 2 years (in age over 65 years)
- Cause of Subclinical Hyperthyroidism impacts risk of progression
- Multinodular Goiter is typically stable without progression
- Graves Disease is more unpredictable in terms of course
- Cardiovascular effects
- Atrial Fibrillation (Relative Risk: 3-5 in age > 60 years old)
- Increased left ventricular mass
- Decreased Heart Rate variability
- Increased Mortality in older patients
- Mortality increased by 20% over 10 years (especially if TSH persistently <0.1)
- Haentjens (2008) Eur J Endocrinol 159(3): 329-41 [PubMed]
- Sgarbi (2010) Eur J Endocrinol 162(3): 569-77 [PubMed]
- Increased Osteoporosis risk in postmenopausal women
- Increased Muscle Weakness and atrophy risk
VIII. Labs
- Thyroid Stimulating Hormone (TSH) decreased
- Serum Free Thyroxine (Free T4) normal
- Serum Free Triiodothyronine (Free T3) nornal
IX. Imaging: 24 hour Radioactive Iodine Uptake Scan (RAIU)
- Indicated in Overt Hyperthyroidism
- Increased >30% at 24 hours
- Decreased <5% at 24 hours
- Silent Thyroiditis
- Postpartum Thyroiditis
- Exogenous Thyroid Hormone intake
X. Evaluation
- See Hyperthyroidism
- Initial lab testing
- Thyroid Stimulating Hormone (TSH)
- If TSH suppressed, obtain:
- If Free T4 and Free T3 increased then evaluate and treat as overt Hyperthyroidism
- Else if Free T4 and Free T3 normal, then continue as Subclinical Hyperthyroidism as below
- Subsequent repeat testing at 3 to 6 months
- Labs
- Thyroid Stimulating Hormone (TSH)
- Serum Free T4
- Serum Free T3
- Overt Hyperthyroidism (increased Free T4 or Free T3)
- Evaluate as Hyperthyroidism (including RAIU Scan)
- See Hyperthyroidism Management
- TSH below 0.1 with normal Free T4, Free T3
- Labs
- Thyrotropin receptor Antibody or TRab (positive in Graves Disease)
- Thyroglobulin (increased in transient Thyroiditis, decreased in excess Thyroid Hormone)
- Obtain 24 hour Radioactive Iodine Uptake Scan (RAIU)
- Increased uptake in Graves Disease (diffuse uptake) and Toxic Nodular Goiter (focal uptake)
- Decreased in transient Thyroiditis (Thyroglobulin high), excess Thyroid Hormone (Thyroglobulin low)
- Consider Hyperthyroidism Management
- Symptomatic or
- Over age 65 years or
- Cardiovascular disease or significant risk factors or
- Osteoporosis or Osteopenia
- Labs
- TSH between 0.1 to 0.45 with normal Free T4, Free T3
- Consider additional evaluation management (esp. if symptomatic) as per TSH <0.1 protocol
- Periodic re-evaluation of TSH every 3-12 months
- Labs
XI. Management
- Indications (American Thyroid Association) for Subclinical Hyperthyroidism with TSH persistently <0.1 mIU/L
- Age 65 years old or older OR
- Age <65 years old with heart disease, Osteoporosis or Hyperthyroidism symptoms
- Age <65 years old and postmenopausal and not on Estrogen or Bisphosphonates
- Other indications
- May consider same management indications as above, for patients with TSH 0.1 to 0.4
- Treatment options
- Treat underlying cause of Subclinical Hyperthyroidism
- Radioactive Iodine (Graves Disease, Toxic Multinodular Goiter, solitary autonomous Nodule)
- Antithyroid Drugs
XII. References
- Donangelo (2011) Am Fam Physician 83(8): 933-8 [PubMed]
- Donangelo (2017) Am Fam Physician 95(11): 710-16 [PubMed]
- Marqusee (1998) Endocrinol Metab Clin North Am 27:37-49 [PubMed]
- Shrier (2002) Am Fam Physician 65(3):431-8 [PubMed]
- Surks (2004) JAMA 291:228-38 [PubMed]
- Woeber (1997) Arch Intern Med 157:1065-8 [PubMed]